PACB: Pacific Biosciences of California, Inc. Stock

by  •  • Comments Off on PACB: Pacific Biosciences of California, Inc. Stock

SIC 3826 – Laboratory Analytical Instruments

Valuation
Market Cap ($M) 542.25
Enterprise Value ($M) 964.25
Book Value ($M) 453.12
Book Value / Share 1.65
Price / Book 1.20
NCAV ($M) -411.16
NCAV / Share -1.50
Price / NCAV -1.32

Profitability (mra)
Return on Invested Capital (ROIC) -0.28
Return on Assets (ROA) -0.21
Return on Equity (ROE) -0.52

Liquidity (mrq)
Quick Ratio 16.64
Current Ratio 18.75

Balance Sheet (mrq) ($M)
Current Assets 585.77
Assets 1,450.05
Liabilities 996.93
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
1 day ago 13G/A Madrone Capital Partners, Llc 9.90 27.50
1 day ago 13G Edmond De Rothschild Asset Management (france) 7.50
3 days ago 13G/A Vanguard Group Inc 6.47 0.00
7 days ago 13G Millennium Management Llc 4.50
02-12 13G/A Nikko Asset Management Americas, Inc. 4.93 -6.82
02-09 13G/A Jackson Square Partners, LLC 3.63 -35.32
02-05 13G/A Sumitomo Mitsui Trust Holdings, Inc. 4.93 -6.82
01-29 13G/A ARK Investment Management LLC 12.90 34.30
01-24 13G/A BlackRock Inc. 9.20 32.96

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPO
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT P
2024-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 o TRANSITION REPORT PURSUA

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-14 6,302,636 12,032,205 52.38
2024-11-13 3,439,410 9,295,920 37.00
2024-11-12 3,062,998 13,437,925 22.79
2024-11-11 3,619,175 14,697,542 24.62

(click for more detail)

Similar Companies
MLAB – Mesa Laboratories, Inc. NAUT – Nautilus Biotechnology, Inc.
NVMI – Nova Ltd. ROP – Roper Technologies, Inc.
SEER – Seer, Inc.


Financial data and stock pages provided by
Fintel.io